{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:14:11Z","timestamp":1763774051126,"version":"3.45.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:54:35Z","timestamp":1744804475000},"page":"829-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-7369","authenticated-orcid":false,"given":"Peihua","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.04.011_bib0002","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.04.011_bib0003","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2025.04.011_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp Biol Med (Maywood)"},{"issue":"10","key":"10.1016\/j.clml.2025.04.011_bib0006","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"7926","key":"10.1016\/j.clml.2025.04.011_bib0007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/hematology.2023000422","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"2023","author":"Epperly","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0009","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1073\/pnas.88.2.603","article-title":"Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine thy-1 gene","volume":"88","author":"Schanberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.clml.2025.04.011_bib0011","first-page":"331","article-title":"Structure and function of the CD7 molecule","volume":"19","author":"Sempowski","year":"1999","journal-title":"Crit Rev Immunol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexmp.2006.06.006","article-title":"The immunophenotype of pre-TALL\/LBL revisited","volume":"81","author":"Lewis","year":"2006","journal-title":"Exp Mol Pathol"},{"issue":"25","key":"10.1016\/j.clml.2025.04.011_bib0013","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.011_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/path.2046","article-title":"Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations","volume":"210","author":"Geissinger","year":"2006","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.clml.2025.04.011_bib0016","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1046\/j.1365-2141.2001.03139.x","article-title":"Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia","volume":"115","author":"Ogata","year":"2001","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"10.1016\/j.clml.2025.04.011_bib0017","first-page":"111","article-title":"CD7 expression in acute myeloid leukemia","volume":"17","author":"Del","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0018","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.leukres.2006.06.001","article-title":"CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype","volume":"31","author":"Chang","year":"2007","journal-title":"Leuk Res"},{"issue":"1\u20132","key":"10.1016\/j.clml.2025.04.011_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10428199809057588","article-title":"CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia","volume":"31","author":"Tien","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.clml.2025.04.011_bib0020","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.7150\/thno.27275","article-title":"T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target","volume":"8","author":"Mayer","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.clml.2025.04.011_bib0021","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.clml.2025.04.011_bib0022","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0023","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"18","key":"10.1016\/j.clml.2025.04.011_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells13181596","article-title":"Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia","volume":"13","author":"Bartoszewska","year":"2024","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR T cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.04.011_bib0027","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.04.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"26","key":"10.1016\/j.clml.2025.04.011_bib0029","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.04.011_bib0030","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.04.011_bib0031","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor T-cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.04.011_bib0032","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"6213","key":"10.1016\/j.clml.2025.04.011_bib0033","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.clml.2025.04.011_bib0034","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1080\/21645515.2019.1571893","article-title":"CRISPR\/Cas9-based genome editing in the era of CAR T cell immunotherapy","volume":"15","author":"Salas-Mckee","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.clml.2025.04.011_bib0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.clml.2025.04.011_bib0036","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0037","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.clml.2025.04.011_bib0038","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An ``off-the-shelf'' fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2025.04.011_bib0039","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"7603","key":"10.1016\/j.clml.2025.04.011_bib0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clml.2025.04.011_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fgene.2018.00021","article-title":"Commentary: programmable base editing of A\u00b7T to G\u00b7C in genomic DNA without DNA cleavage","volume":"9","author":"Matsoukas","year":"2018","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.clml.2025.04.011_bib0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1365-2141.1996.d01-1900.x","article-title":"Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL","volume":"95","author":"Baum","year":"1996","journal-title":"Br J Haematol"},{"issue":"3\u20134","key":"10.1016\/j.clml.2025.04.011_bib0043","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10428199709051778","article-title":"Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin","volume":"26","author":"Frankel","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.04.011_bib0044","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","article-title":"A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells","volume":"2","author":"Kamiya","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.011_bib0045","article-title":"Targeted CD7 CAR T-cells for treatment of T-lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.clml.2025.04.011_bib0046","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/bloodadvances.2022008402","article-title":"SECTM1-based CAR T cells enriched with CD7-low\/negative subsets exhibit efficacy in CD7-positive malignancies","volume":"7","author":"Wei","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.011_bib0047","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"issue":"25","key":"10.1016\/j.clml.2025.04.011_bib0048","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.04.011_bib0049","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.04.011_bib0051","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"issue":"Suppl 3","key":"10.1016\/j.clml.2025.04.011_bib0052","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.HS9.0000843336.97011.4c","article-title":"S110: a novel and successful CD7 gene knockout CAR-T cell therapy for relapsed or refractory T-cell hematologic malignancies","volume":"6","author":"Yang","year":"2022","journal-title":"HemaSphere"},{"issue":"11","key":"10.1016\/j.clml.2025.04.011_bib0053","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.04.011_bib0054","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1182\/blood-2022-165733","article-title":"A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.04.011_bib0055","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","article-title":"CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.04.011_bib0056","article-title":"Anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma: a phase 1\/2 trial","author":"Ghobadi","year":"2024","journal-title":"Res Sq"},{"issue":"10","key":"10.1016\/j.clml.2025.04.011_bib0057","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.011_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152457","article-title":"Outcomes with chimeric antigen receptor T-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"14","author":"Shahzad","year":"2023","journal-title":"Front Immunol"},{"issue":"S3","key":"10.1016\/j.clml.2025.04.011_bib0059","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000972444.78727.01","article-title":"P1389: a novel and successful CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory\/relapsed mixed phenotype acute leukemia (MPAL)","volume":"7","author":"Zhang","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.04.011_bib0060","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2024-196853","article-title":"CD7-targeted CAR-T cell therapy shows promising efficacy and safety in treating refractory\/relapsed peripheral T-cell lymphoma: phase I clinical trial","volume":"144","author":"Yang","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0061","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1111\/bjh.19445","volume":"204","author":"Cao","year":"2024","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.clml.2025.04.011_bib0062","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.04.011_bib0063","first-page":"1","article-title":"Novel strategies to manage CAR-T cell toxicity","volume":"24","author":"Mulvey","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.clml.2025.04.011_bib0064","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcyt.2024.04.075","article-title":"Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors","volume":"26","author":"Miller","year":"2024","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.clml.2025.04.011_bib0065","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.4049\/jimmunol.170.5.2349","article-title":"CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets","volume":"170","author":"Aandahl","year":"2003","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.04.011_bib0066","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1182\/blood-2023-185361","article-title":"Comparative analysis of immune effector cell-associated hematotoxicity (ICAHT) and infection incidence following CD19-targeted CAR-T therapy versus CD7-targeted CAR-T therapy","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.04.011_bib0067","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clml.2025.04.011_bib0068","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2025.04.011_bib0069","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clml.2025.04.011_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and future directions of dual-target chimeric antigen receptor T-cell therapy in preclinical and clinical studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.clml.2025.04.011_bib0071","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.04.011_bib0072","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10.1016\/j.clml.2025.04.011_bib0073","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:21Z","timestamp":1763773821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025001429"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}